Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102752 · ClinicalTrials.gov registry record · Phase 1
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
A Phase 1 study of Neoplasms and Pancreatic Neoplasms, sponsored by Threshold Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 9
- Study locations
NCT00102752 is a Phase 1 study of Neoplasms and Pancreatic Neoplasms that has completed, run by Threshold Pharmaceuticals. The registered enrollment target is 47 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT00102752, a Phase 1 study of Neoplasms and Pancreatic Neoplasms, has completed, sponsored by Threshold Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Glufosfamide
Study Locations (9)
São Paulo
- Fundação Pio XII - Hospital de Câncer de Barretos - Barretos
- Universidade Federal de São Paulo - Hospital São Paulo - São Paulo
- Hospital Israelita Albert Einstein - São Paulo
Rio Grande do Sul
- Hospital Mãe de Deus - Porto Alegre
- Hospital Nossa Senhora da Conceição - Porto Alegre
Arizona
- Arizona Cancer Center - Tucson
Indiana
- Indiana Cancer Center - Indianapolis
Kentucky
- Norton Healthcare Cancer Center - Louisville
BH
- Hospital de Doenças Cardiovasculares - Biocor - Nova Lima
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102752
The ClinicalTrials.gov registry entry for NCT00102752 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is Threshold Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00102752 reports 9 study locations spanning 6 distinct geographic areas - top geographies include São Paulo, Rio Grande do Sul, Arizona.
Frequently Asked Questions
What is clinical trial NCT00102752 about?
NCT00102752 is a clinical study titled "Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer". The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine.
What is the current status of trial NCT00102752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2004-12. Estimated completion is 2007-07.
What conditions does trial NCT00102752 study?
This clinical trial studies the following conditions: Neoplasms, Pancreatic Neoplasms.
What interventions are being tested in trial NCT00102752?
The interventions under investigation include: Gemcitabine (DRUG), Glufosfamide (DRUG).
Who is sponsoring clinical trial NCT00102752?
This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00102752 being conducted?
This trial has 9 study locations across Arizona, Indiana, Kentucky, BH, Rio Grande do Sul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.